This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly’s GLP-1 franchise remains highly successful, with Mounjaro sales up 99% and Zepbound sales up 175% in 2025, but the article argues the stock is expensive at 39x P/E versus 26x for the S&P 500 and 23x for the average drug stock. It highlights patent-expiration risk, likely generic competition, and intensifying GLP-1 rivalry from Novo Nordisk and Pfizer. The piece is more of a valuation and competitive-risk warning than a catalyst-driven update.

Analysis

The market is still pricing LLY like a near-monopoly on a multi-year growth curve, but the more important issue is duration of earnings power, not just peak sales. In this category, the economic value migrates quickly from first mover to whoever can lower friction, extend adherence, and win payer access; that tends to compress margins before it shows up in headline demand. A premium multiple can work if the franchise behaves like software, but obesity drugs are still a biologic market with patent cliffs, supply normalization, and active substitution risk.

The first-order winner from any slowdown in LLY multiple expansion is not necessarily the obvious direct rival; it is the basket of companies with cleaner optionality and less perfection already priced in. NVO benefits if the market starts valuing breadth of platform and pill convenience over injectable share leadership, while PFE’s upside is more convex because expectations are low and any credible long-acting program can rerate the stock off a depressed base. Second-order, contract manufacturers and fill-finish suppliers should see volatile order flow as buyers diversify away from a single dominant supplier and as rival pipelines move from development into launch preparation.

The contrarian miss is that “competition is coming” is not automatically bearish for the category; it can expand total market size by improving access and acceptance, but that is usually a slower, more muted benefit than the multiple compression from saturation fear. The near-term setup is still mostly a valuation trade: over the next 3-6 months, any evidence of slower prescription growth, payer pushback, or adverse event headlines could drive disproportionate de-rating because the stock is still priced for uninterrupted execution. Over 12-24 months, the bigger question is whether the company can reinvest its windfall into a second and third growth leg before the GLP-1 curve normalizes.

Key Decisions for Investors

• Trim/avoid initiating fresh longs in LLY into strength; use any 5-10% rebound as a re-entry opportunity for short-dated put spreads if prescription commentary cools over the next 1-2 quarters.
• Long NVO vs. short LLY on a 3-6 month horizon as a relative-value expression of platform diversification and less demanding expectations; target multiple compression in LLY without taking full sector beta.
• Initiate a small speculative long in PFE only against a hard stop if pipeline headlines improve; the setup is a low-consensus call option on obesity-adjacent R&D with asymmetry if validation arrives within 6-12 months.
• If options liquidity allows, buy 6-9 month LLY put spreads financed by selling far OTM puts after a rally; this captures de-rating risk while limiting premium outlay.
• Monitor payer and supply-chain indicators monthly; if access tightens or inventory drawdowns appear, reduce all obesity-exposed longs because the next leg of the trade is likely multiple compression, not fundamental collapse.